Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
154.5 USD | +0.66% | -1.56% | +3.84% |
Mar. 12 | Balchem Insider Sold Shares Worth $840,985, According to a Recent SEC Filing | MT |
Feb. 23 | Balchem Insider Sold Shares Worth $1,700,613, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 39.27 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.84% | 4.98B | B- | ||
+16.84% | 66.26B | A- | ||
-3.18% | 47.33B | A- | ||
+15.53% | 40.92B | B+ | ||
+0.88% | 17.76B | C+ | ||
+11.20% | 16.58B | B+ | ||
-10.85% | 15.14B | C+ | ||
+30.57% | 13.41B | A- | ||
-0.43% | 9.3B | A | ||
-2.46% | 8.55B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Balchem Corporation - Nasdaq
- Ratings Balchem Corporation